Hyseq Pharmaceuticals Appoints Nina Giles to Lead Business Development Efforts
SUNNYVALE, Calif., June 24 /PRNewswire-FirstCall/ -- Hyseq Pharmaceuticals, Inc. (Nasdaq: HYSQ - News), today announced Nina V. Giles as vice president, business development. Ms. Giles joins Hyseq as a member of the senior management team and will lead the company's business development efforts.
"Nina brings to Hyseq a demonstrated track record for driving and accelerating corporate growth and development through intellectual property licensing, product in-licensing and strategic collaborations and alliances with pharmaceutical and biotechnology companies," said Dr. Ted W. Love, president and chief executive officer of Hyseq Pharmaceuticals. "As we continue to look for additional ways to bring significant revenue into the company, we are excited to have someone as experienced and successful as Nina leading business development efforts here at Hyseq."
Ms. Giles joins Hyseq from Incyte Genomics, Inc. where she held various positions in the commercial organization from 1997 to 2002; most recently serving as vice president, business development, where she was a leading contributor to Incyte's revenue generation. Previously, she held both analyst and management positions at Frost & Sullivan from 1995 to 1997. Ms. Giles received her bachelor's degree from the University of California at Davis.
About Hyseq
Hyseq Pharmaceuticals, Inc. is engaged in research and development of novel biopharmaceutical products from its collection of proprietary genes discovered using its high-throughput screening-by-hybridization platform. Hyseq's screening-by-hybridization platform provided a significant advantage in discovering novel, rarely-expressed genes, and assembly of one of the most important proprietary databases of full-length human gene sequences. Hyseq is expanding and accelerating its research activities to further elucidate the role of novel genes in its proprietary database. Hyseq's database includes genes which encode a number of therapeutically important classes of molecules including chemokines, growth factors, stem cell factors, interferons, integrins, proteases, hormones, receptors, and other potential protein therapeutics or drug targets.
Information about Hyseq Pharmaceuticals is available at www.hyseq.com or by phoning 408-524-8100.
Statements contained in this press release which are not historical in nature, are intended to be, and are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Act of 1995. Forward-looking statements may be identified by words such as "believe," "expect," "anticipate," "should," "may," "estimate," "goals," and "potential," among others. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to unanticipated difficulties and delays relating to gene identification, drug discovery and clinical development processes; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes; uncertainties relating to patent protection and regulatory approval; and uncertainties relating to our ability to obtain substantial additional funds required for progress in drug discovery and development. These and other factors are identified and described in more detail in our periodic reports filed from time to time with the SEC, including without limitation our Annual Report on Form 10-K for the year ended December 31, 2001. We disclaim any intent or obligation to update these forward-looking statements.
SOURCE: Hyseq Pharmaceuticals, Inc. |
